H.C. Wainwright initiated coverage of Innoviva (INVA) with a Buy rating and $40 price target The firm says Innoviva is a diversified company marketing multiple commercial products that is benefiting from “durable” royalty streams on mass market respiratory disease franchises.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA:
- Innoviva initiated with an Overweight at Cantor Fitzgerald
- Innoviva announces zoliflodacin NDA granted Priority Review by FDA
- Innoviva Specialty Therapeutics announces FDA accepts NDA for zoliflodacin
- Innoviva Elects Board Members and Approves Compensation
- Innoviva subsidiary announces U.S. commercial availability of ZEVTERA